Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bicalutamide
Drug ID BADD_D00271
Description Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Indications and Usage For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Marketing Status approved
ATC Code L02BB03
DrugBank ID DB01128
KEGG ID D00961
MeSH ID C053541
PubChem ID 2375
TTD Drug ID D0V9BD
NDC Product Code 49711-1504; 49711-1509; 51846-1028; 62559-890; 71205-577; 0904-6019; 53104-7664; 16714-816; 60429-177; 62559-680; 43265-7195; 46014-1111; 82920-004; 54893-0001; 16729-023; 58623-0068; 63629-8308; 15308-0360; 47335-485
UNII A0Z3NAU9DP
Synonyms bicalutamide | 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide | Casodex | Cosudex | ICI-176334 | ICI 176334
Chemical Information
Molecular Formula C18H14F4N2O4S
CAS Registry Number 90357-06-5
SMILES CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.0040.008015%Not Available
Loss of libido19.08.03.0030.005624%Not Available
Lung disorder22.02.07.0010.002812%Not Available
Lung infiltration22.01.02.004--Not Available
Lymphadenopathy01.09.01.0020.005624%Not Available
Lymphoma01.12.01.001; 16.20.01.0010.001406%Not Available
Malaise08.01.01.0030.024044%
Melaena24.07.02.013; 07.12.02.004--Not Available
Meningioma17.20.01.005; 16.30.01.0050.004921%Not Available
Menopausal symptoms21.02.02.002--Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.006609%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.003515%Not Available
Metastases to spine16.22.02.007; 15.09.03.0070.002109%Not Available
Micturition urgency20.02.02.006--
Multiple fractures15.08.02.005; 12.04.02.009--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.003515%
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Necrosis08.03.03.001; 24.04.02.0060.001406%Not Available
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Nephrolithiasis20.04.01.002--
Nephrotic syndrome20.05.01.0020.001406%
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.0050.001406%
Neuropathy peripheral17.09.03.003--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 13 Pages